Outpatient utilization of medicines in the Republic of Srpska in 2009-2017
Sažetak
Background: Monitoring and measuring of the medicines use enables to assess quality use of medicines. The aim of this study was to analyze utilization patterns of medicines use and to compare the results with other countries.
Methods: A retrospective, observational study to analyse outpatient medicines use between 2009 and 2017. Data on medicines utilization were retrieved from the national database in the Public Institute of Health. Medicines utilization was calculated and analyzed using the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) methodology. The results were expressed in defined daily doses per 1000 inhabitants per day (DDDs).
Results: Total medicines utilization increased, from 448 DDDs (2009) to 1036 DDDs (2017). Cardiovascular medicines were the most used, and their share in the total utilization increased from 36,6% (2009) to 44,4% (2017). The most used were angiotensin-converting enzyme inhibitors, plain and in combinations with diuretics, namely enalapril. The share of medicines used in diabetes in the total utilization increased from 3,9% (2009) to 5,1% (2017). Metformin and glimepiride accounted about 83% of the blood glucose lowering medicines group (A10B). Of antithrombotic medicines, the most used were platelet aggregation inhibitors excluding heparin (B01AC), namely acetylsalicylic acid whose use tripled since 2009. Non-steroid antiinflamatory and antirheumatic medicine were the most used, namely diclofenac.
Conclusion: The trend of increased medicines utilization was observed by this study. This finding is comparable with other countries. Variations between countries in the preferred medicines within a class as well as the extent of medicines use were observed. These differences were probably consistent to, but not solely attributable to, differences in local guidelines and reimbursement policies.
Reference
Republic of Srpska Government. National Medicines Policy. Banja Luka: Ministry of Health and Social Welfare, 2006.
The Organisation for Economic Co-operation and Development (OECD). Health at a Glance 2017: OECD Indicators [Internet]. Paris: OECD Publishing, 2017 [cited 2019 Jul 4]. Available from: http://www.oecd-library.
Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing Use of Prescription Drugs in the United Kingdom. Pharmacoepidemiol Drug Saf. 2016;25(6):628-36.
Marković-Peković V, Škrbić R, Godman B, Gustafsson L. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev. Pharmacoecon. Outcomes Res. 2012;12(5):661-71.
The Organisation for Economic Co-operation and Development (OECD). Health at a Glance 2018: OECD Indicators [Internet]. Paris: OECD Publishing, 2018 [cited 2019 Jul 4]. Available from: http://www.oecd-library.
Richards M. A report for the Secretary of State for Health by Professor Sir Mike Richards [Internet]. London: Crown Copyright, 2010. Extent and causes of international variations in drug usage [cited 2019 Sep 4]. Available from: http://www.gov.uk/government/publications/extent-and-causes-of-international-variations-in-drug-usage.
Ewbank L, Omojomolo D, Sullivan K, McKenna H. The rising cost of medicines to the NHS. What’s the story? Briefing. [Internet]. London: Тhe Kings Fund, 2018 [cited 2019 Jul 4]. Available from: http://www.kingsfund.org.uk/sites/default/files/2018-04/Rising-cost-of-medicines.pdf.
Marković-Peković V, Škrbić R, Petrović A, Vlahović-Palčevski V, Mrak J, Bennie M, et al. Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2016;16(5):609-18.
Republika Srpska Institute for Statistics. Women and men in Republika Srpska. Bulletin no 9. [Internet]. Banja Luka: Republički zavod za statistiku, 2017 [cited 2019 Sep 15]. Available from: http://www.rzs.rs.ba.
Ministry of Health and Social Welfare of the Republic of Srpska. Guidelines for clinical practice [Internet]. Banja Luka: Ministry, 2004 [cited 2019 Jul 4]. Available from: http://www.vladars.net.
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2019 [Internet]. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2019 [cited 2019 Jul 17]. Available from: http://www.whocc.no/.
Patel SR, Shah AM, Shah RB, Buch JG. Evaluation of drug utilization pattern of antimicrobials using ATC/DDD system in intensive care unit of a tertiary-care teaching hospital. Int J Med Sci Public Health 2016;5(1):80-4.
Rosli R, Dali AF, Abd Aziz, Abdullah AH, Ming LC, Mannan MM. Drug Utilization on Neonatal Wards: A Systematic Review of Observational Studies. Front. Pharmacol. 2017; 8:27.
Bojanić Lj, Marković-Peković V, Škrbić R, Stojaković N, Đermanović M, Bojanić J, et al. Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. Front.Pharmacol.2018;9:445.
Versporten A, Bolokhovets G, Ghazaryan L, Abilova V, Pyshnik G, Spasojević T, et al. Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe. Lancet Infect. Dis.2014;14:381-87.
Ferrer P, Balların E, Sabate M, Laporte JR, Schoonen M, Rottenkolber M, et al. Sources of European drug consumption data at a country level. Int J Public Health. 2014;59(5):877-87.
Marković-Peković V, Stoisavljević-Šatara S, Škrbić R. Utilization of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, five years study. Pharmacepidemiol Drug Safety, 2009;18:320-26.
Marković-Peković V, Stoisavljevic-Šatara S, Škrbic R. Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia and Herzegovina. Eur J Clin Pharmacol 2010;66:177-86.
Belloni A, Morgan D, Paris V. Pharmaceutical expenditure and policies: past trends and future challenges [Internet]. OECD Health Working Papers, no 87. Paris: OECD Publishing, 2016 [cited 2019 Sep 4]. Available from: http://www.oecd-ilibrary.org.
Stanetić K, Račić M, Petrović V, Jatić Z, Savić S, Kusmuk S. Prevencija najčešćih hroničnih bolesti. [Internet]. Udruženje doktora porodične medicine. Banja Luka: Atlantik bb, 2017 [cited 2019 Sept 7]. Available from: http://porodicnamedicina.com.
Agencija za lekove i medicinska sredstva Srbije. Promet i potrošnja gotovih lekova za humanu upotrebu u Republici Srbiji u 2009.godini [Internet]. Beograd: Agencija za lekove i medicinska sredstva Srbije, 2010 [cited 2019 Sep 1]. Available from: https://www.alims.gov.rs.
Agencija za lekove i medicinska sredstva Srbije. Promet i potrošnja gotovih lekova za humanu upotrebu u Republici Srbiji u 2010.godini [Internet]. Beograd: Agencija za lekove i medicinska sredstva Srbije, 2011 [cited 2019 Sep 1]. Available from: https://www.alims.gov.rs.
Agencija za lekove i medicinska sredstva Srbije. Promet i potrošnja gotovih lekova za humanu upotrebu u Republici Srbiji u 2017.godini [Internet]. Beograd: Agencija za lekove i medicinska sredstva Srbije, 2018 [cited 2019 Sep 1]. Available from: https://www.alims.gov.rs.
Agencija za lijekove i medicinske proizvode-HALMED. Potrošnja lijekova u Hrvatskoj 2013.-2017. [Internet]. Zagreb: HALMED, 2018 [cited 2019 Sep 1]. Available from: http://www.halmed.hr.
Agencija za lijekove i medicinske proizvode-HALMED. Potrošnja lijekova u Hrvatskoj 2009. - 2013. [Internet]. Zagreb: HALMED, 2015 [cited 2019 Sep 1]. Available from: http://www.halmed.hr.
Agencija za ljekove i medicinska sredstva Crne Gore-CALIMS. Potrošnja ljekova u Crnoj Gori za period 2014-2015.godine [Internet]. Podgorica: CALIMS, 2016. [cited 2019 Sep 1]. Available from: http://www.calims.me.
Ezzati M, Riboli E. Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals. Science 2012;21;337(6101):1482-7.
Cannon G, Gupta P, Gomes F, Kerner J, Parra W, Weiderpass E, et al. ICCC-4 Working Group. Prevention of cancer and non-communicable diseases. Asian Pac J Cancer Prev. 2012;13(4 Suppl):3-11.
Mikkelsen B, Williams J, Rakovac I, Wickramasinghe K, Hennis A, Shin H, et al. Life course approach to prevention and control of non-communicable diseases. BMJ. 2019;364: l257.
Republic of Srpska Government. Ministry of Health and Social Welfare. Policy for Improvement of Health of the Population in the Republic of Srpska by the Year 2020. Banja Luka: Ministry of Health and Social Welfare, 2012.
Sakshaug, S (red), Legemiddelforbruket i Norge 2013–2017 [Drug Consumption in Norway 2013–2017].[Internet].Legemiddelstatistikk 2018:1, Oslo: Folkehelseinstituttet, 2018 [cited 2019 Sept 5]. Available from: http://www.fhi.no.
Australian Government. Australian Institute of Health and Welfare. Medicines for cardiovascular disease. Cat.no CVD 80. [Internet]. Canberra: AIHW, 2017 [cited 2019 Sept 15]. Available from: http://www.aihw.gov.au.
Polluzzi E, Korhonen MJ. Drug utilization research in the area of cardiovascular medicines. In: Elseviers M, Wettermark B, Almarsdóttir AB, Andersen M, Benko R, Bennie M, et al., editors. Drug Utilization Research:Methods and Applications. Wiley-Blackwell (Canada): Toronto, Ontario, 2016. Chapter 27, p. 284-293.
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet.2012;380:2197–223.
Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.
Clark H. NCDs: a challenge to sustainable human development. Lancet.2013;381:510-11.
Republika Srpska Institute for Statistics. Women and men in Republika Srpska. Bulletin no 1. [Internet]. Banja Luka: Republički zavod za statistiku, 2003 [cited 2019 Sep 15]. Available from: http://www.rzs.rs.ba.
Cardiology Society of Republic of Srpska. European Guidelines for the Prevention of Cardiovascular Diseases. Version 2007. [Internet]. Banja Luka: Udruženje kardiologa Republike Srpske, 2007 [cited 2019 Sep 9]. Available from: http://www.kardiolozi-rs.org/
European Society of Cardiology. The Task Force on ACE-inhibitors: Lopez-Send J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J. 2004;25(16):1454-70.
European Society of Cardiology. Ruilope L, Cereso C, Segura J, Garcia-Donaire. Calcium channel blockers and cardiovascular protection. [Internet]. e-journal of the ESC Council for Cardiology Practice 2008; 6: No 28. [cited 2019 Sep 9]. Available from: https://www.escardio.org.
European Society of Cardiology. CVD Prevention in Clinical Practice (European Guidelines on) Guidelines. ESC Clinical Practice Guidelines. EHJ 2016;37:2315-81.
European Society of Cardiology. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J.2018;39:3021-104.
Weisfeldt ML, Zieman SJ. Advances in the prevention and treatment of cardiovascular disease. Health Aff (Millwood) 2007;26(1):25-37.
Lisauskienė I, Garuolienė K, Gulbinovič J. Utilization of cardiovascular medicines and cardiovascular mortality in Lithuania, Sweden and Norway in 2003-2012. Medicina (Kaunas). 2017;53(4):259-67.
Jarari N, Rao N, Rao Peela J, Ellafi KA, Shakila S, Said AR, et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens. 2016; 22:7.
Finnish Medicines Agency Fimea. Drug consumption in years 2014-2017.[Internet]. [cited 2019 Sept 5]. Available from: www.fimea.fi.
Sarganas G, Knopf H, Grams D, Neuhauser H. Trends in Antihypertensive Use and Blood Pressure Control Among Adults With Hypertension in Germany. Am J Hypertens. 2016;29(1):104-13.
Dezsi CA. The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? Am J Cardiovasc Drugs 2016;16:255-66.
Grassi G, Robles NR, Seravalle G, Fici F. Lercanidipine in the management of hypertension: An update. J Pharmacol Pharmacother 2017; 8:155-65.
Health Insurance Fund of Republika Srpska. Price Lists and Codes. Medicines. [Internet]. [cited 2019 Sept 16]. Available from: https://www.zdravstvo-srpske.org/files/cjenovnici/lijekovi.pdf.
The Agency for Medicinal Products and Medical Devices. Annual reports on the medicines sale in Bosnia and Herzegovina. [Internet]. [cited 2019 Sep 10]. Available from: http://www.almbih.gov.ba/.
Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JG, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393(10186):2155-67.
Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11(1):121-9.
Dowd CM, Tillmann JJ. Therapeutic Interchange from Rosuvastatin to Atorvastatin in a Veteran Population. Fed Pract. 2015;32(12):20-24.
Republika Srpska Institute for Statistics. Women and men in Republika Srpska. Bulletin no 6. [Internet]. Banja Luka: Republički zavod za statistiku, 2012. [cited 2019 Sep 15]. Available from: www.rzs.rs.ba.
American Diabetes Association (2018a). 8. Pharmacological approach to glycemic treatment: standards of medical care in diabetes-2018. Diabetes care 41 (Supplement 1), S73-S85.
National Institute for Health and Care Excellence. Type 2 diabetes in adults: management (Clinical guideline NG28). [Internet]. London: NICE, 2019 [cited 2019 Sept 15]. Available from: https://www.nice.org.uk/guidance/ng28.
Ministry of Health of Republic of Serbia. National clinical guideline Diabetes mellitus. Second amended Ed. Beograd: Agency for Accreditation of Health Care Institutions of Serbia, 2012.
Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care. 2018;41(1):69-78.
Wilkinson S, Douglas I, Stirnadel-Farrant H, Fogarty D, Pokrajac A, Smeeth L,et al. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017. BMJ Open 2018;8:e022768.
Moreno Juste A, Menditto E, Orlando V, Monetti VM, Miguel AG, Rubio FG, et al. Treatment Patterns of Diabetes in Italy: A Population-Based Study. Front. Pharmacol.10:870.
Pavlica R, Topličanin I, Vrcić Keglević M. Ten-year Trends in the Morbidity of Diabetes Mellitus and Antidiabetic Drug Utilization in Croatia: A Study Based on Routinely Collected Data. Int J Family Med.2016;2016:9837496.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).